Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30033864 | 0.84 | ALDH1A1 (0.42) | ALDH1A1KDM4EPTPN1ERN1NFE2L2 | |
| SCHEMBL7826405 | 0.84 | ALDH1A1 (0.42) | ALDH1A1KDM4EPTPN1ERN1NFE2L2 | |
| SCHEMBL25078602 | 0.80 | KDM4E (0.39) | ALDH1A1KDM4EPTPN1ERN1NFE2L2 | |
| SCHEMBL11131347 | 0.80 | NFE2L2 (0.33) | NFE2L2ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL27140027 | 0.79 | ALDH1A1 (0.40) | ALDH1A1KDM4EPTPN1ERN1MAPT | |
| SCHEMBL22867745 | 0.79 | ALDH1A1 (0.44) | ALDH1A1KDM4EERN1MEN1MAPT | |
| SCHEMBL2800253 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL3376315 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL9081120 | 0.77 | PDE7A (0.40) | ALDH1A1KDM4EPTPN1NFE2L2MEN1 | |
| SCHEMBL4866236 | 0.76 | TDP1 (0.55) | ALDH1A1KDM4EPTPN1ERN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-106661031-B | Pyrrolopyrimidine compounds or its salt, pharmaceutical composition and application containing it | 大鹏药品工业株式会社 | 2019-07-23 | — | — | CN | disclosed |
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | TAIHO PHARMACETUICAL CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3395345-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| EP-3103802-B1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-11-08 | — | — | EP | disclosed |
| CN-106661031-A | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | 大鹏药品工业株式会社 | 2017-05-10 | — | — | CN | disclosed |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1549315-A4 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| EP-1549315-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004024078-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| CN-1184478-A | Thiazole derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1998-06-10 | — | — | CN | disclosed |
| EP-0816362-A1 | THIAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | ALDH1A1 563/4885KDM4E 702/4885PTPN1 3313/4885 |
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | MCL1, TP53, DPYD | ALDH1A1 1826/4885KDM4E 3124/4885PTPN1 1402/4885 |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | KRAS, DPYD, PSTPIP2 | ALDH1A1 1400/4885KDM4E 697/4885PTPN1 40/4885 |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | WASHC5, NME1, NHERF1 | ALDH1A1 1158/4885KDM4E 938/4885PTPN1 37/4885 |
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | DHPS, DUT, CDKN1A | ALDH1A1 451/4885KDM4E 463/4885PTPN1 2250/4885 |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | KRAS, DPYD, PSTPIP2 | ALDH1A1 1400/4885KDM4E 697/4885PTPN1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.